Zilebesiran: A Promising Antihypertensive Therapy Inhibiting Angiotensinogen Synthesis

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Genetics

Background:

• Systemic hypertension affects over a billion people globally, with suboptimal control rates despite available treatments.
• Novel therapeutic strategies are crucial for effective blood pressure management.
• The renin-angiotensin-aldosterone system (RAAS) is a key target for antihypertensive therapies.

Purpose of the Study:

• To evaluate the efficacy and safety of zilebesiran, a novel siRNA targeting angiotensinogen (AGT) production.
• To assess the dose-dependent effects of zilebesiran on blood pressure and serum AGT levels.
• To explore the potential of gene silencing as a therapeutic approach for hypertension.

Main Methods:

• Zilebesiran, an siRNA, was administered subcutaneously to post-transcriptionally silence the AGT gene in the liver.
• Phase I clinical trials were conducted to assess safety, tolerability, and pharmacodynamics.
• Dose-dependent effects on blood pressure and serum angiotensinogen were measured.

Main Results:

• A dose-dependent reduction in blood pressure and serum angiotensinogen levels was observed.
• Sustained effects of zilebesiran were noted for up to 6 months post-administration.
• The safety profile was promising, with most adverse events being mild to moderate.

Conclusions:

• Zilebesiran demonstrates potential as a novel antihypertensive therapy by inhibiting the RAAS at the angiotensinogen level.
• The drug exhibits a favorable safety profile and sustained efficacy, warranting further investigation.
• Phase II trials are ongoing to confirm efficacy and determine optimal dosing for hypertension treatment.